Tag: Medicine

According to TAU study, based on data from 300,000 tests for Covid-19.

A new study at Tel Aviv University found that the British variant (termed: B.1.1.7) of Covid-19 is 45% more contagious than the original virus. The researchers relied on data from about 300,000 PCR tests for Covid-19 obtained from the COVID-19 testing lab, which was established in collaboration with the Electra Group. According to the researchers, “The study proves that active monitoring of at-risk population and prioritized vaccination programs can prevent hundreds of deaths.” The new study was conducted by Prof. Ariel Munitz and Prof. Moti Gerlitz of the Department of Clinical Microbiology and Immunology at the Sackler Faculty of Medicine, together with Dr. Dan Yamin and PhD student Matan Yechezkel from the Laboratory for Epidemic Modeling and Analysis (LEMA) at the Department of Industrial Engineering, all at Tel Aviv University. The study’s results were published in the prominent scientific journal Cell Reports Medicine. The Electra-TAU laboratory was established in March 2020, right after the outbreak of the first wave of the pandemic in Israel. To date, it has analyzed hundreds of thousands of tests from all over the country – from public drive-in test facilities, as well as programs targeting specific populations – such as ‘Shield for Fathers and Mothers’ which routinely ran tests in at-risk hotspots like retirement homes. Prof. Ariel Munitz explains: “We use a kit that tests for three different viral genes. In the British variant, also known as B.1.1.7, one of these genes, the S gene, has been erased by the mutation. Consequently, we were able to track the spread of the variant even without genetic sequencing.” According to Prof. Munitz, the data from the lab shows that the spread of the British variant in Israel was very rapid: On December 24, 2020 only 5% of the positive results were attributed to the British variant. Just six weeks later, in January 2021, this variant was responsible for 90% of Covid-19 cases in Israel. The current figure is about 99.5%. “To explain this dramatic increase, we compared the R number of the SARS-CoV-2 virus with the R of the British variant. In other words, we posed the question: How many people, on the average, contract the disease from every person who has either variant? We found that the British variant is 45% – almost 1.5 times – more contagious.”

Vaccine Saved Hundreds

In the second stage of the study, the researchers segmented contagion by age groups. The results indicated that the turning point for the 60+ population compared to other age groups occurred two weeks after 50% of Israel’s 60+ population received their first vaccine shot: “Until January we saw a linear dependence of almost 100% between the different age groups in new cases per 1,000 people,” says Dr. Dan Yamin. “Two weeks after 50% of the 60+ population received the first dose of the vaccine this graph broke sharply and significantly. During January a dramatic drop was observed in the number of new cases in the 60+ group, alongside a continued rise in the rest of the population. Simply put, since more than 90% of those who died from Covid-19 were over 60, we can say that the vaccine saved hundreds of lives – even in the short run.”

Active Monitoring of At-Risk Populations

Moreover, the new study proves that active monitoring of at-risk populations works. “There is a threshold value for determining whether a specific test is positive or negative for the virus – with a lower value indicating a higher viral load,” says Prof. Munitz. “When we compared the threshold values of the different genes in 60+ residents of retirement homes with the values measured in 60+ persons in the general population, we saw significantly higher values in the retirement homes. This means that the viral load in retirement homes was lower compared to the rest of the population. Since the residents of retirement homes are tested routinely, while other people are usually tested only when they don’t feel well or have been in contact with someone who had tested positive for the virus, we conclude that constant monitoring of at-risk populations is a method that works. It is important to emphasize: the relatively low viral load was found in retirement homes despite the fact that the British variant had already begun to spread in all populations. Consequently, we show that monitoring retirement homes, together with vaccination that gives precedence to vulnerable populations, prevent illness and mortality.” Dr. Yemin concludes: “Due to crowded conditions, large households and age distribution in the Israeli population, the coronavirus had a more favorable environment for spreading in Israel compared to most Western countries. Our message to the world is that if with our problematic starting point a distinct decline was identified, other Western countries can certainly expect the curve to break – despite the high contagion of the British variant – with a dramatic drop in severe cases following the vaccination of 50% of the older population, alongside targeted testing at risk epicenters.” Featured image: Left to Right: Prof. Ariel Munitz, Dr. Dan Yamin and Prof. Moti Gerlitz

Expected to revolutionize the field of skin cancer diagnosis.

Melanoma is a life-threatening cancer, but its immediate diagnosis can save lives. An innovative optical technology that can distinguish between different types of cancer has now been developed in the laboratory of Professor Abraham Katzir, from the Raymond and Beverly Sackler Faculty of Exact Sciences at Tel Aviv University, which enables real time diagnosis of melanoma. Based on special optical fibers, the technology will enable every dermatologist to determine the character of a suspicious lesion automatically, and particularly if it is melanoma. Non-invasive, immediate, and automatic, this process may lead to a dramatic change in the field of diagnosing and treating skin cancer, and possibly other types of cancer as well. The technology has been tried successfully on about one hundred patients in a major hospital in Israel. The findings were published in the Journal Medical Physics.

Seeing Skin Cancer’s True Colors

When a suspicious lesion is found on the skin, during a routine examination, it is removed in a minor surgical procedure and sent to a laboratory for testing. A pathologist diagnoses the lesion and determines whether it is melanoma. In most cases where melanoma is discovered early, when it is still superficial and less than one-millimeter-thick and it is removed, the patient recovers. Late diagnosis, when the melanoma is more than one-millimeter-thick, significantly reduces the chances of recovery and is life-threatening. “The idea that guided us in developing the technology was that in the visible range, there are various substances, having various colors, which are not characteristic of each substance. On the other hand, in the infrared region, various substances have different ‘colors’ of a sort, depending on the chemical makeup of each substance,” says Professor Katzir. “Therefore, we figured that with the help of devices that can identify these ’colors’, healthy skin and each of the benign and malignant lesions would have different ’colors’, which would enable us to identify melanoma.” Professor Katzir’s research group developed special optical fibers that are transparent in the infrared. The group, in collaboration with physicists Professor Yosef Raichlin of Ariel University, Dr. Max Platkov of the Negev Nuclear Research Center, and Svetlana Bassov of Professor Katzir’s group, developed a system, based on these fibers, in accordance with the requirements of evaluating skin. The researchers connected one end of this type of fiber to a device that measures the ’colors’ in the infrared, and touched the other end lightly, for several seconds, to a lesion on a patient’s skin. The fiber made it possible to check the ’color’ of the lesion right away. Clinical trials were then carried out on suspicious lesions in about one hundred patients. With the help of the new system, physicists performed measurements of the ’color’ of each lesion, before it was removed and sent to a pathology laboratory. The researchers showed that all of the lesions that were determined by pathologists as being of a certain type, such as melanoma, had a characteristic ’color’ in the infrared. Each type of lesion had a different ’color’. “The technology gives us a kind of ‘fingerprint’, which makes it possible to diagnose the various lesions by measuring their characteristic ’colors’”, says Professor Katzir. “In this way, lesions can be diagnosed using a non-invasive optical method, and the physician and the patient receive the results automatically and immediately.  This is unlike the test that is routinely used, which involves surgery, and the pathological diagnosis takes a long time.” Following the success of the study, the researchers plan to confirm the evaluation method on hundreds of patients.   ​

Non-invasive, immediate, and automatic

In conclusion, Professor Katzir says: “Melanoma is a life-threatening cancer, so it is very important to diagnose it early on, when it is still superficial. The innovative system will enable every dermatologist to determine the character of a suspicious lesion automatically, and particularly if it is melanoma. This system has the potential to cause a dramatic change in the field of diagnosing and treating skin cancer, and perhaps other types of cancer as well. The challenge will be to make this technology, which is still expensive, something that will be used in every hospital or clinic.”

TAU researchers identify proteins that cause intestinal disease.

Your FOMO may be compromising your physical and mental health.

400 students received their second COVID-vaccine on campus this month.

Promotes production of important antibodies in breast milk.

We may have some good news: Covid-19 vaccination of nursing mothers might actually work to protect not only them, but their babies as well. This was found in a new study conducted jointly by Tel Aviv University and the Tel Aviv Sourasky Medical Center – Ichilov, in order to find out whether Pfizer’s COVID-19 vaccine was effective in producing antibodies in breast milk, and also to determine the qualities of these antibodies (whether they have the potential to neutralize the virus). The study was conducted during the months January and February 2021, shortly after the vaccines arrived in Israel, and included 10 breastfeeding mothers. The volunteers received two shots of the vaccine, 21 days apart, and the levels of antibodies in both their blood and breast milk were tested at four points in time, following vaccination. Blood and breast milk, it was found, are well synchronized with regard to the rise of the levels of the specific antibodies generated by the vaccine. In both blood and breastmilk, the significant increase occurs 14 days after the first shot, and continues 7 days after the second shot. The antibodies that develop in breastmilk hold the potential to neutralize the virus, and thus prevent the disease, by blocking the virus from binding with receptors on host cells. The leading research team at Tel Aviv University included Dr. Yariv Wine and the PhD student Aya Kigel from the Shmunis School of Biomedicine and Cancer Research at the Faculty of Life Sciences. The team at the Lis Maternity and Women’s Hospital at the Tel Aviv Sourasky Medical Center was led by Dr. Michal Rosenberg-Friedman and Prof. Ariel Many. The paper is currently undergoing peer review and can be read here >>

Innovative technology of BLAVATNIK CENTER for Drug Discovery may save boy suffering from rare neurological syndrome.

In December 2019, the BLAVATNIK CENTER for Drug Discovery at Tel Aviv University was presented with a challenge which demanded flexibility and thinking outside the box. Prof. Ehud Gazit, Founder and Academic Director of the BLAVATNIK CENTER for Drug Discovery at Tel Aviv University, received an email from Scott Reich, a very worried father. Scott’s son Eli, only eight months old at the time, had just been diagnosed with the ultra-rare FOXG1 syndrome, a neurological disorder that severely impacts brain development. With only about 700 known cases worldwide, predominantly children with severe disabilities, this devastating condition attracts little research and has no cure. Determined to save his son, Scott searched all over the world for experts who could develop a treatment for the rare syndrome. The advice and recommendations of leading scientists and health professionals led him to the BLAVATNIK CENTER at TAU in Israel, which specializes in the field of drug repurposing: repurposing FDA-approved medications and other safe substances to help people with rare diseases, all too often overlooked by the big pharmaceutical companies. Dr. Eddy Pichinuk, Head of the HTS and Biological Assays Unit at BLAVATNIK CENTER, whose team was already conducting research for several other families affected by rare diseases, willingly accepted the new challenge. Dr Pichinuk and his team quickly obtained a sample of Eli’s cells, which had been deposited in a biobank for rare disease biosamples, and established a personalized drug-screening platform to test these cells against known, safe, FDA-approved molecules that could be repurposed. Essentially, they were looking for any drug (originally developed for some other purpose) that would increase the amount of FOXG1 protein in Eli’s brain, making up for the damaging deficiency caused by the mutation. The researchers were well aware that this might be Eli’s only hope for a more normal life: once a safe and effective drug is identified, it can be repurposed to offer Eli and others like him compassionate treatment. “Our screening platform is based on a luminescent protein, expressed in fireflies, that replaces the faulty protein in Eli’s cells,” explains Eddy. “We are screening a library of about 7,000 FDA-approved substances, initially developed to treat a range of diseases, such as cancer, psychiatric disorders, or various inflammatory syndromes. By testing each drug’s interaction with the marked protein in Eli’s cells, we have so far discovered several potentially helpful drug candidates. As we begin to see the light at the end of the tunnel, we continue to search for additional drugs.” In the next stage, the researchers will use advanced methods of genetic engineering to transform skin samples from Eli and his parents into stem cells and then into neurons. Ultimately, they will test the effect of the chosen drugs on Eli’s neurons. Determined and optimistic, they aim to restore more normalized brain development.

Thinking Outside the Box

Dr. Avi Raveh, the BLAVATNIK CENTER’s Chief Scientific Officer, explains that the Center offers a unique research approach, applying personalized medicine methodology to rare diseases. “We respond to requests from families all over the world, often at the last moment before they lose hope. Unlike large research institutions, we resemble a small and dynamic startup, eliminating or speeding up any bureaucracy and getting right down to the crux of the challenge. In Eli Reich’s case, with the time window for brain development closing fast, this flexibility is crucial. I truly hope that we can help him.” “Coming to Israel and working with the BLAVATNIK CENTER has been a good experience so far,” says Scott. Thanks to the Israeli spirit of collaboration, researchers at the Weizmann Institute of Science and Ben-Gurion University of the Negev have also been recruited to join the mission of saving Eli. He remains hopeful: “When we heard the devastating diagnosis, I said to my wife Ilissa: ‘We have to go to Israel. In Israel, we’ll find the know-how, experience and out-of-the-box thinking that we need.’ Reaching out through the American Jewish community and our Israeli friends, we got in touch with the BLAVATNIK CENTER for Drug Discovery, and immediately felt at home. The team is very creative, they work fast and are sincerely dedicated to finding a treatment for FOXG1 syndrome – they’re not just looking to publish a paper in a scientific journal. For us, this genuine commitment is extremely important. The BLAVATNIK CENTER team is doing everything they can so that Eli and others with FOXG1 Syndrome may live and hopefully enjoy more productive lives.” For more information about FOXG1 and Eli Reich, please visit BELIEVE IN A CURE Featured image: The Reich Familiy

New study proves biological treatment can be a suitable alternative to antibiotics.

In a groundbreaking new study led by Dr. Natalia Freund and doctoral candidate Avia Watson at the TAU Sackler Faculty of Medicine, researchers were able to develop a “biological antibiotic” and demonstrates that human antibodies can offer an alternative to the traditional chemical antibiotics. The study was conducted in collaboration with laboratories in the United States and China and published in the prestigious scientific journal Nature Communications.

During the past century, antibiotics have served as the main treatment against bacteria, being both efficient and cheap. Antibiotics are chemical agents, designed to block and destroy specific cells, such as microbial cells. However, since some biological mechanisms are common to both human and microbial cells, the range of antibiotics that can safely be used without harming the patient is limited. For example, cell wall components of many strains of microbes are common to human cells; therefore, any damage caused to the microbial cell walls can lead to extensive damage to body systems. Furthermore, in recent years the number of microbial strains that are resistant to existing antibiotics has grown, which presents new challenges of defending the body from microbes in the post-antibiotic era.

For these reasons, Dr. Natalia Freund and her laboratory team have spent the recent years searching for a biological alternative to known antibiotics. Dr. Freund explains, “Advances in biological medicine have enabled us to rout the germs in new ways that are not based solely on antibiotics, allowing for a solution to the challenge posed by resistant germs. Our study is an initial proof of the concept of employing monoclonal antibodies (derived from single cells) as an effective therapy for combating bacterial pathogens”. Antibodies are proteins that are produced naturally by our immune response following infection or a vaccine. They harbor many advantages such as specificity, stability and safety. This is why antibodies are today in widespread use in the clinic for treatment of cancer, autoimmune diseases and viral infections such as COVID-19.

Tuberculosis as Test Case

The research team chose Tuberculosis, which is caused by infection of the bacilli Mycobacterium tuberculosis, as a test case and were able, for the first time ever, to create an effective treatment based on anti-bacterial antibodies that developed naturally during infection (the antibodies were extracted from a patient who had been infected, and has since recovered, from tuberculosis). Another reason for the choice of tuberculosis is that although the vaccine against tuberculosis was developed 100 years ago (and is based on the attenuated bacillus bovis (BCG) strain), it is not effective for adults and does not prevent infection. In addition, in recent years, more and more strains of disease have developed that are resistant to the only treatment currently available: treatment with antibiotics. Since tuberculosis bacteria are highly contagious and are transmitted through the air and damaging to the lungs, the spread of untreated resistant strains of tuberculosis constitutes a real hazard. Today, about a quarter of the world’s population is infected with tuberculosis, with the rates of drug-resistant strains peaking   as high as 40% in some countries. In Israel, there are about 200 active tuberculosis cases every year.

 

Dr. Natalia Freund and her research team

Future Targets: Pneumonia and Staphylococcal Infections

Due to the size and complexity of the tuberculosis bacillus, previous efforts to isolate monoclonal antibodies against it have been futile. The researchers in Dr. Freund’s laboratory have succeeded in isolating two types of antibodies which contributed to a 50% reduction of the bacterial levels in mice relative to other mice that were not treated with antibodies. These antibodies have been found to be effective against three different strains of the tuberculosis bacterium and are expected to be effective also against additional strains that have not yet been investigated, including strains that are resistant to antibiotics

Following the success of the study, Dr. Freund’s laboratory is currently exploring the possibility of extending the “biological” substitute for antibiotics to include other diseases. “The demonstrated case for this study will enable us to expand on our future work to include diseases such as pneumonia and staphylococcal infections,” says Dr. Freund.

A new TAU study examines the difficulties experienced by children with different levels of autism and their parents during Israel’s first lockdown during the coronavirus crisis (in the spring of 2020). The data shows that the drastic changes in the children’s routines and their prolonged stay in their homes instead of their special education had serious implications for the behavior and development of the children and impacted their parent’s ability to support them

The study was led by Dr. Itay Tokatly-Latzer, Prof. Orit Karnieli-Miller and Prof. Yael Leitner from the TAU Sackler Faculty of Medicine, in collaboration with the Tel-Aviv Sourasky Medical Center, and was published in the academic journal ‘Autism’.

Lack of Routine Caused Regression

The study group consisted of the parents of 25 children with autism who shared the difficulties they faced during lockdown with the researchers in real time. Some children would for instance refuse to go to sleep at night – screaming and restless, they would stay awake all through the night. Others experienced behavioral regression, returning to repetitive and stereotypical movements that had initially improved.

At the same time, however, the researchers note that there were families who experienced it differently and who found creative ways to help their children get through the crisis in a positive way: One couple chose to go along with the particular interests of their child, engaging in repetitive cake baking. The parents of another child who needed to be in constant movement, bought their son a trampoline so that he could spend his excess energy inside their home.

Support and Guidance Programs for Parents of Children with Autism

Prof. Karnieli-Miller: “Lockdowns are difficult for all of us, but all the more so for families with autistic children. For these children, even the slightest change of routine can cause harm and throw them off balance. The study showed that in many instances the parents were left helpless as they did not have the tools and the professional knowledge required to deal with the situation. The parents need to be given the tools, support and guidance in order to deal with this huge challenge and enable them to create a ‘flexible routine’ for their children.

“The findings of the study show that during periods of lockdowns the State must do whatever it takes to prevent the closing down of special education, in order to prevent causing harm to children with special needs. If the State nevertheless decides that such steps be taken, it must immediately implement assistance and guidance programs for parents of children with autism. The parents need to receive professional help and better tools for caring for their children.”

TAU research proves connection for first time, can be base for cancer drugs.

What makes cancer cells different from ordinary cells in our bodies? Can these differences be used to strike at them and paralyze their activity? This basic question has bothered cancer researchers since the mid-19th century. The search for unique characteristics of cancer cells is a building block of modern cancer research. A new study led by researchers from Tel Aviv University shows, for the first time, how an abnormal number of chromosomes (aneuploidy) — a unique characteristic of cancer cells that researchers have known about for decades — could become a weak point for these cells. The study could lead, in the future, to the development of drugs that will use this vulnerability to eliminate the cancer cells.

The study, which was published in Nature, was conducted in the laboratory of Dr. Uri Ben-David of the Sackler Faculty of Medicine at Tel Aviv University, in collaboration with six laboratories from four other countries (the United States, Germany, the Netherlands, and Italy).

Aneuploidy is a hallmark of cancer. While normal human cells contain two sets of 23 chromosomes each — one from the father and one from the mother — aneuploid cells have a different number of chromosomes. When aneuploidy appears in cancer cells, not only do the cells “tolerate” it, but it can even advance the progression of the disease. The relationship between aneuploidy and cancer was discovered over a century ago, long before it was known that cancer was a genetic disease (and even before the discovery of DNA as hereditary material).

According to Dr. Ben-David, aneuploidy is actually the most common genetic change in cancer. Approximately 90% of solid tumors, such as breast cancer and colon cancer, and 75% of blood cancers, are aneuploid. However, our understanding of the manner in which aneuploidy contributes to the development and spread of cancer is limited.

In the study, the researchers used advanced bioinformatic methods to quantify aneuploidy in approximately 1,000 cancer cell cultures. Then, they compared the genetic dependency and drug sensitivity of cells with a high level of aneuploidy to those of cells with a low level of aneuploidy. They found that aneuploid cancer cells demonstrate increased sensitivity to inhibition of the mitotic checkpoint – a cellular checkpoint that ensures the proper separation of chromosomes during cell division.

They also discovered the molecular basis for the increased sensitivity of aneuploid cancer cells. Using genomic and microscopic methods, the researchers tracked the separation of chromosomes in cells that had been treated with a substance that is known to inhibit the mitotic checkpoint. They found that when the mitotic checkpoint is perturbed in cells with the proper number of chromosomes, cell division stops. As a result, the chromosomes in the cells separate successfully, and relatively few chromosomal problems are created. But when this mechanism is perturbed in aneuploid cells, cell division continues, resulting in the creation of many chromosomal changes that compromise the cells’ ability to divide, and even cause their death.

The study has important implications for the drug discovery process in personalized cancer medicine. Drugs that delay the separation of chromosomes are undergoing clinical trials, but it is not known which patients will respond to them and which will not. The results of this study suggest that it will be possible to use aneuploidy as a biological marker, based on possibility to find the patients who will respond better to these drugs. To put it another way, it will be possible to adapt drugs that are already in clinical trials for use against tumors with specific genetic characteristics.

In addition, the researchers propose focusing the development of new drugs on specific components of the mechanism of chromosomal separation, which were identified as especially critical to aneuploid cancer cells. The mitotic checkpoint is made up of several proteins. The study shows that the aneuploid cells’ sensitivity to inhibition of the various proteins is not identical, and that some proteins are more essential to cancer cells than others. Therefore, the study provides motivation for developing specific drugs against additional proteins in the mitotic checkpoint.

“It should be emphasized that the study was done on cells in culture and not on actual tumors, and in order to translate it to treatment of cancer patients, many more follow-up studies must be conducted. If they hold true in patients, however, our findings would have a number of important medical implications,” Dr. Ben-David says.

The study was conducted in collaboration with laboratories from five countries: Dr. Zuzana Storchová, (Technische Universität Kaiserslautern, Germany), Dr. Jason Stumpff (University of Vermont, USA), Dr. Stefano Santaguida (University of Milano, Italy), Dr. Floris Foijer (University of Groningen, the Netherlands), and Dr. Todd Golub (The Broad Institute of MIT and Harvard, USA).